20/20 GeneSystems, Inc.

20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. Early Detection of Lung Cancer: 20/20 is developing a blood test for the early detection of lung cancer in parallel with Ortho Clinical Diagnostics ("OCD") (a Johnson & Johnson company) who licensed rights to the technology from 20/20 (co-exclusive).